Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today ...

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive ...

Collagen is considered a dietary supplement that can offer comprehensive health benefits. Check this list of the best ...

Sanofi-owned biotech company Genzyme has sued rival Sarepta Therapeutics in Delaware federal court for allegedly infringing two patents related to Sarepta's Duchenne muscular dystrophy (DMD ...

No articles found. Genzyme Corporation did not contribute to any primary research papers from Nature Index journals in the current 12 month window. The following affiliated institutions are wholly ...

Counsel have not yet appeared for the defendant. The case is 2024CV030484, Genzyme Corp et al v. Graesser Bzdek, Kristin. Biotech & Pharmaceuticals February 15, 2024, 10:03 PM ...

Cambridge-based biotech Genzyme Corp. will be paying a $32.5 million settlement to resolve allegations that it inappropriately marketed a surgical device. According to a release from the U.S ...

(Reuters) - Genzyme Corp agreed to pay $32.59 million, admit wrongdoing and enter a deferred prosecution agreement to resolve U.S. criminal charges over its marketing of the surgical implant ...

By Emily Micucci Cambridge-based Genzyme Corp. will move part of its operations in Framingham to Westborough by the end of the year, taking with it 500 employees, the company said.

Two and a half years after buying local biotech Genzyme Corp. for $20.1 billion, Sanofi SA’s chief executive Wednesday said the deal has paid off handsomely for his company, sparking a business ...